1[1]Tollefson G D, Sanger T M. Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy[J].Schixophr Res, 1999,35(Suppl):S13-S21.
2[2]Hiller A, Maier W, Wetzer H, et al. Risreridone in the treatment of disorders with a combined psychotic and depressive syndrome: a functional approach[J]. Pharmacopsychiatry, 1992,25(4):213-217.
3[3]Marder S R, Advis J M, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials[J]. J Clin Psychiatry, 1997,58(11):538-546.
4[4]Tollefson G D, Anderson S W, Tran P V. The course of depressive symptoms in predicing replapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone[J]. Bilo Psychiatry, 1999,46(3):363-373.
5[5]Tollefson G D, Sanger T M, Beasley C M, et al. A double-blind, controlled comparision of the novel antipsychotic olanzapine versus haloperidol of placebo on anxious and depressive symptoms accompanying schizophrenia[J]. Biol Psychiatry, 1998,43(11):803-810.
6[6]Tollefson G D, Beasley C M, Tran P V, et al. Olanzapine versus halperdol in the treatment of schizophrenia and schizoaffctive and schizophreniform disordes: results of an international collaborative trial[J]. Am J Psychiatry, 1997,154(4):457-465.
7[7]Zarate C A Jr, Rothschild A, Fletcher K E, et al. Clinical predictors of acute response with quetiapine in psychotic mood disorders[J].J Clin Psychiatry, 2000,61(3):185-189.
